Navigation Links
ChromaDex® Announces Letter of Intent Signed with Glanbia Nutritionals for Partnership on pTeroPure®
Date:1/24/2012

IRVINE, Calif., Jan. 24, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of its branded patent-pending pterostilbene, pTeroPure, announced today it has signed a letter of intent with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company, for the distribution of pTeroPure. Glanbia Nutritionals will serve as the primary distributor of pTeroPure in North America.

pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan, and is the central ingredient in its recently launched BluScience™ line of dietary supplements.

pTeroPure is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (an antioxidant phytochemical that tends to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.

"Partnering with a large, exceptionally strong company like Glanbia is a tremendous next step in expanding pTeroPure's adoption into numerous consumer products. With our upcoming human clinical data release and our various patents pending, in combination with Glanbia's strong distribution base, we are now very well-positioned to more rapidly accelerate our national expansion of pTeroPure," said William Spengler, President of ChromaDex.

"ChromaDex's pTeroPure is an excellent addition to our product portfolio due to its superior bioavailability and range of potential health benefits," said Richard Hazel, CEO of Glanbia Nutritionals (NA), Inc. "The new distribution agreement will allow us to utilize our extensive market experience and national sales resources towards promoting ChromaDex's innovative new product line and will benefit Glanbia Nutritionals by strengthening our position as a leader in the ingredients industry."

About Glanbia Nutritionals (NA), Inc.:

Glanbia Nutritionals is a division of Glanbia plc, an international nutritional solutions and cheese group, headquartered in Kilkenny, Ireland. The Group has 4,300 employees worldwide, with operations in Ireland, the UK, Germany, USA, Canada, Mexico and China, as well as strategic international joint ventures in the UK, USA and Nigeria. Glanbia is listed on both the Dublin and London Stock Exchange. Glanbia is a global supplier of nutritional ingredients, functional ingredients and customized premix solutions. Glanbia Nutritionals is on the forefront in the exploration of science and the dynamics that drive the growing nutrition industry. For more information visit glanbianutritionals.com or contact Thomas Monroe, Marketing, 760-438-0089, tmonroe@glanbia.com.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Contact:

Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

pTeroPure® Contact:

Jeremy Bartos
ChromaDex Product Development
949-600-9694
jeremyb@pteropure.com

*These statements have not been evaluated by the Food and Drug Administration.  This product is not intended to diagnose, treat, cure or prevent any disease.

 


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChromaDex®s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... WAYNE, N.J. , May 3, 2017 /PRNewswire/ ... systems that contribute to quality enhancement and cost ... results from a study of contemporary practice demonstrating ... a first-line therapy for critically ill patients. The ... the Company,s newer large volume MEGA ® ...
(Date:5/2/2017)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce a ... AB that allows for the marketing and distribution ... analyses through the MarketResearch.com website. The new ... to complete product descriptions and tables of contents from ...
(Date:5/2/2017)... , May 2, 2017  CIVCO Radiotherapy, the ... solutions, announced today that Nat Geissel ... CIVCO since 2012 and has served as vice ... vice president and general manager, and most recently, ... "I am extremely proud of what CIVCO Radiotherapy ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... If you are thinking of a visit to San Francisco , fall ... the perfect time to visit. , Business Architecture Associates is pleased to offer 5 days ... as a 4-½ day package for individuals, and as 4-½ day corporate package for up ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... Shoreview, MN (PRWEB) , ... May 24, 2017 ... ... manufacturer of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had ... network now consists of a mix of domestic and rest of world (ROW) ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
Breaking Medicine News(10 mins):